,CAR-TB-NHL

Jiqin Zhang1, Yongxian Hu2,3,4,5, Jiaxuan Yang6

  • 1Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China. zjqjeremy@163.com.

Nature
|August 31, 2022
PubMed
概括

这项研究引入了一种新的非病毒CRISPR-Cas9方法,用于制造增强的仿真抗原受体 (CAR) - T细胞. 这些CAR- T细胞在治疗侵袭性B细胞非霍奇金淋巴瘤方面具有很高的安全性和有效性.